A case of marked efficacy of low-dose UFT against metastatic bladder cancer

The two regimens of treatment consisted of either cisplatin and gemcitabine or methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC), which has been widely adopted for muscle-invasive bladder cancer. But because of its potential toxicity, its tolerability has been troublesome, especially for very elderly patients. Herein, we report a bladder cancer case with multiple metastases which were controlled by low-dose UFT. At the same time, the chemosensitivity of 5-FU combined with uracyl or 5-chloro-2, 4-dihydroxypyridine (CDHP). Four invasive bladder cancer cell lines were evaluated with a collagen gel droplet embedded drug sensitivity test (CD-DST). Three of four cell lines showed an increasing sensitivity to 5-FU with the combination of uracil or CDHP. Examinations with CD-DST may provide important scientific evidence for determining suitable chemotherapy for patients with advanced bladder cancer.